Oncology and Hematology
Oncology and Hematology Clinical Practice
Stay current with Oncology and Hematology education that fits how you practice. ReachMD offers practical, on-demand clinical content for oncologists, hematologists, oncology nurses, pharmacists, fellows, APPs, and the full cancer care team. Explore expert discussions, case-based programs, CME/CE opportunities, industry features, and news across solid tumors, hematologic malignancies, biomarker-driven care, immunotherapy, targeted therapy, supportive care, and more.
Use this page to find relevant oncology and hematology content fast. Browse Project Oncology episodes, jump into CME/CE activities, review expert perspectives, or explore timely updates on evolving treatment strategies and standards of care. New content is added regularly, so you can stay current with emerging evidence, guideline updates, and multidisciplinary approaches to cancer care on your schedule.
Start with the latest programs below or browse by content type to find the Oncology and Hematology education most relevant to your practice.
256-270 of 298
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
MinuteCE®Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
Nadia Harbeck, MD, PhD
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
MinuteCE®Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
MinuteCE®Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Recent updates from adjuvant trials in HR+/HER2- EBC
MinuteCE®Recent updates from adjuvant trials in HR+/HER2- EBC
Nadia Harbeck, MD, PhD
Warm Autoimmune Hemolytic Anemia: How Antibody-Based Therapies Are Revolutionizing Its Management
CME/CEWarm Autoimmune Hemolytic Anemia: How Antibody-Based Therapies Are Revolutionizing Its Management
Caroline Piatek, MD
Irina Murakhovskaya, MD
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
MinuteCE®Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
Ritu Salani, MD, MBA
- advertisement
Diversity in HER2 Expression Among Gynecologic Cancers
MinuteCE®Diversity in HER2 Expression Among Gynecologic Cancers
Ritu Salani, MD, MBA
Significance of HER2 Expression in Solid Tumors
MinuteCE®Significance of HER2 Expression in Solid Tumors
Shubham Pant, MD, MBBS
Ritu Salani, MD, MBA
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
MinuteCE®HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
Shubham Pant, MD, MBBS
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
MinuteCE®Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
Shubham Pant, MD, MBBS
Ritu Salani, MD, MBA
Shubham Pant, MD, MBBS
Ritu Salani, MD, MBA
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
MinuteCE®Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
Ritu Salani, MD, MBA
- advertisement
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
MinuteCE®Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
Ritu Salani, MD, MBA
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
MinuteCE®Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
Shubham Pant, MD, MBBS
HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease
CME/CEHER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease
Justin Gainor, MD
Jacob Sands, MD
